Edition:
United States

Epizyme Inc (EPZM.OQ)

EPZM.OQ on NASDAQ Stock Exchange Global Select Market

14.93USD
17 Jan 2018
Change (% chg)

-- (--)
Prev Close
$14.93
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
158,642
52-wk High
$20.40
52-wk Low
$9.35

Chart for

About

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of... (more)

Overall

Beta: 2.09
Market Cap(Mil.): $1,034.04
Shares Outstanding(Mil.): 69.28
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 203.19 16.42
EPS (TTM): -- -- --
ROI: -- -7.35 33.31
ROE: -- -29.01 17.56

BRIEF-Epizyme announces pricing of public offering of common stock

* Epizyme announces pricing of public offering of common stock

Sep 14 2017

BRIEF-Epizyme reports Q2 loss of $0.48/shr

* Epizyme reports second quarter 2017 financial results and clinical and business progress

Aug 04 2017

BRIEF-US Oncology Research and Epizyme establish collaboration to identify non-hodgkin lymphoma patients with EZH2 mutations

* US Oncology Research and Epizyme establish collaboration to identify non-hodgkin lymphoma patients with EZH2 mutations

Aug 01 2017

BRIEF-Epizyme announces Tazemetostat to be evaluated in NCI-COG pediatric MATCH trial

* Epizyme announces Tazemetostat to be evaluated in NCI’s recently initiated NCI-COG pediatric MATCH trial Source text for Eikon: Further company coverage:

Jul 24 2017

Competitors

  Price Chg
Eisai Co., Ltd (4523.T) ¥6,303 -145.00
Novartis AG (NOVN.S) CHF83.76 +0.52
GlaxoSmithKline plc (GSK.L) 1,359.80 +0.60
Celgene Corporation (CELG.OQ) $102.02 --

Earnings vs. Estimates